Navigation Links
Aton Pharma Announces Distribution Partnership in Brazil
Date:5/12/2008

LAWRENCEVILLE, N.J., May 12 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a distribution agreement with Meizler Biopharma S/A to commercialize CUPRIMINE(R) and SYPRINE(R) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.

"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country."

"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, Meizler's President. "Cuprimine and Syprine both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."

Meizler is a Brazilian Pharmaceutical company, headquartered in Sao Paulo, active in both the out-patient and hospital segments of the pharmaceutical industry. The company currently markets more than 40 products on the Brazilian market and has international partnerships in place with companies in the United States, Europe and Asia, to which Meizler provides various regulatory and commercial services. Using an advanced management and logistics system, Meizler is able to rapidly supply its high quality products to providers and patients. For more information, see http://www.meizler.com.br.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT: Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
7. EUSA Pharma Completes Acquisition Of Cytogen Corporation
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
11. Onyx Pharmaceuticals to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):